Tahikinin (Serbian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Tahikinin" in Serbian language version.

refsWebsite

Global rank Serbian rank

20nih.gov

4^th place

8^th place

13doi.org

2^nd place

4^th place

4web.archive.org

1^st place

4bentham-direct.org

low place

3archive.org

6^th place

5^th place

1jneurosci.org

low place

1elsevier.com

610^th place

653^rd place

archive.org

Maggio JE (1988). „Tachykinins”. Annu. Rev. Neurosci. 11: 13—28. PMID 3284438. doi:10.1146/annurev.ne.11.030188.000305.
Salomé N, Stemmelin J, Cohen C, Griebel G (2006). „Selective blockade of NK2 or NK3 receptors produces anxiolytic- and antidepressant-like effects in gerbils”. Pharmacol. Biochem. Behav. 83 (4): 533—9. PMID 16624395. doi:10.1016/j.pbb.2006.03.013.
Louis C, Stemmelin J, Boulay D, Bergis O, Cohen C, Griebel G (2008). „Additional evidence for anxiolytic- and antidepressant-like activities of saredutant (SR48968), an antagonist at the neurokinin-2 receptor in various rodent-models”. Pharmacol. Biochem. Behav. 89 (1): 36—45. PMID 18045668. doi:10.1016/j.pbb.2007.10.020.

bentham-direct.org

Chahl LA (2006). „Tachykinins and neuropsychiatric disorders”. Curr Drug Targets. 7 (8): 993—1003. PMID 16918327. doi:10.2174/138945006778019309. Архивирано из оригинала 28. 03. 2009. г. Приступљено 09. 10. 2018.
Groneberg DA, Harrison S, Dinh QT, Geppetti P, Fischer A (2006). „Tachykinins in the respiratory tract”. Curr Drug Targets. 7 (8): 1005—10. PMID 16918328. doi:10.2174/138945006778019318. Архивирано из оригинала 28. 03. 2009. г. Приступљено 09. 10. 2018.
Improta G, Broccardo M (2006). „Tachykinins: role in human gastrointestinal tract physiology and pathology”. Curr Drug Targets. 7 (8): 1021—9. PMID 16918330. doi:10.2174/138945006778019354. Архивирано из оригинала 28. 03. 2009. г. Приступљено 09. 10. 2018.
Quartara L, Altamura M (2006). „Tachykinin receptors antagonists: from research to clinic”. Curr Drug Targets. 7 (8): 975—92. PMID 16918326. doi:10.2174/138945006778019381. Архивирано из оригинала 28. 03. 2009. г. Приступљено 09. 10. 2018.

doi.org

Maggio JE (1988). „Tachykinins”. Annu. Rev. Neurosci. 11: 13—28. PMID 3284438. doi:10.1146/annurev.ne.11.030188.000305.
Dornan WA, Vink KL, Malen P, Short K, Struthers W, Barrett C (1993). „Site-specific effects of intracerebral injections of three neurokinins (neurokinin A, neurokinin K, and neurokinin gamma) on the expression of male rat sexual behavior”. Physiol. Behav. 54 (2): 249—58. PMID 7690487. doi:10.1016/0031-9384(93)90107-Q.
Duffy RA (2004). „Potential therapeutic targets for neurokinin-1 receptor antagonists”. Expert Opin Emerg Drugs. 9 (1): 9—21. PMID 15155133. doi:10.1517/eoed.9.1.9.32956.
Salomé N, Stemmelin J, Cohen C, Griebel G (2006). „Selective blockade of NK2 or NK3 receptors produces anxiolytic- and antidepressant-like effects in gerbils”. Pharmacol. Biochem. Behav. 83 (4): 533—9. PMID 16624395. doi:10.1016/j.pbb.2006.03.013.
Louis C, Stemmelin J, Boulay D, Bergis O, Cohen C, Griebel G (2008). „Additional evidence for anxiolytic- and antidepressant-like activities of saredutant (SR48968), an antagonist at the neurokinin-2 receptor in various rodent-models”. Pharmacol. Biochem. Behav. 89 (1): 36—45. PMID 18045668. doi:10.1016/j.pbb.2007.10.020.
Spooren W, Riemer C, Meltzer H (2005). „Opinion: NK3 receptor antagonists: the next generation of antipsychotics?”. Nat Rev Drug Discov. 4 (12): 967—75. PMID 16341062. doi:10.1038/nrd1905.
Chahl LA (2006). „Tachykinins and neuropsychiatric disorders”. Curr Drug Targets. 7 (8): 993—1003. PMID 16918327. doi:10.2174/138945006778019309. Архивирано из оригинала 28. 03. 2009. г. Приступљено 09. 10. 2018.
Groneberg DA, Harrison S, Dinh QT, Geppetti P, Fischer A (2006). „Tachykinins in the respiratory tract”. Curr Drug Targets. 7 (8): 1005—10. PMID 16918328. doi:10.2174/138945006778019318. Архивирано из оригинала 28. 03. 2009. г. Приступљено 09. 10. 2018.
Improta G, Broccardo M (2006). „Tachykinins: role in human gastrointestinal tract physiology and pathology”. Curr Drug Targets. 7 (8): 1021—9. PMID 16918330. doi:10.2174/138945006778019354. Архивирано из оригинала 28. 03. 2009. г. Приступљено 09. 10. 2018.
Boot JD; de Haas S; Tarasevych S; et al. (2007). „Effect of an NK1/NK2 receptor antagonist on airway responses and inflammation to allergen in asthma”. Am. J. Respir. Crit. Care Med. 175 (5): 450—7. PMID 17170385. doi:10.1164/rccm.200608-1186OC.
Navari RM (2007). „Fosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting”. Expert Opin Investig Drugs. 16 (12): 1977—85. PMID 18042005. doi:10.1517/13543784.16.12.1977.
Hickman MA; Cox SR; Mahabir S; et al. (2008). „Safety, pharmacokinetics and use of the novel NK-1 receptor antagonist maropitant (Cerenia) for the prevention of emesis and motion sickness in cats”. J. Vet. Pharmacol. Ther. 31 (3): 220—9. PMID 18471143. doi:10.1111/j.1365-2885.2008.00952.x.
Quartara L, Altamura M (2006). „Tachykinin receptors antagonists: from research to clinic”. Curr Drug Targets. 7 (8): 975—92. PMID 16918326. doi:10.2174/138945006778019381. Архивирано из оригинала 28. 03. 2009. г. Приступљено 09. 10. 2018.

elsevier.com

linkinghub.elsevier.com

Dornan WA, Vink KL, Malen P, Short K, Struthers W, Barrett C (1993). „Site-specific effects of intracerebral injections of three neurokinins (neurokinin A, neurokinin K, and neurokinin gamma) on the expression of male rat sexual behavior”. Physiol. Behav. 54 (2): 249—58. PMID 7690487. doi:10.1016/0031-9384(93)90107-Q.

jneurosci.org

Carter MS, Krause JE (1990). „Structure, expression, and some regulatory mechanisms of the rat preprotachykinin gene encoding substance P, neurokinin A, neuropeptide K, and neuropeptide gamma”. J. Neurosci. 10 (7): 2203—14. PMID 1695945.

nih.gov

ncbi.nlm.nih.gov

Grace RC, Lynn AM, Cowsik SM (2001). „Lipid induced conformation of the tachykinin peptide Kassinin”. J. Biomol. Struct. Dyn. 18 (4): 611—21, 623—5. PMID 11245256.
Carter MS, Krause JE (1990). „Structure, expression, and some regulatory mechanisms of the rat preprotachykinin gene encoding substance P, neurokinin A, neuropeptide K, and neuropeptide gamma”. J. Neurosci. 10 (7): 2203—14. PMID 1695945.
Maggio JE (1988). „Tachykinins”. Annu. Rev. Neurosci. 11: 13—28. PMID 3284438. doi:10.1146/annurev.ne.11.030188.000305.
Helke CJ, Krause JE, Mantyh PW, Couture R, Bannon MJ (1990). „Diversity in mammalian tachykinin peptidergic neurons: multiple peptides, receptors, and regulatory mechanisms”. Faseb J. 4 (6): 1606—15. PMID 1969374.
Avanov AIa (1992). „Tachykinins and conformational aspects of their interactions with receptors”. Mol. Biol. (Mosk). 26 (1): 5—24. PMID 1324401.
Dornan WA, Vink KL, Malen P, Short K, Struthers W, Barrett C (1993). „Site-specific effects of intracerebral injections of three neurokinins (neurokinin A, neurokinin K, and neurokinin gamma) on the expression of male rat sexual behavior”. Physiol. Behav. 54 (2): 249—58. PMID 7690487. doi:10.1016/0031-9384(93)90107-Q.
Online Mendelovsko nasleđivanje kod čoveka (OMIM) TAC1 -162320
Online Mendelovsko nasleđivanje kod čoveka (OMIM) TAC3 -162330
Alvaro G, Di Fabio R (2007). „Neurokinin 1 receptor antagonists--current prospects”. Curr Opin Drug Discov Devel. 10 (5): 613—21. PMID 17786860.
Duffy RA (2004). „Potential therapeutic targets for neurokinin-1 receptor antagonists”. Expert Opin Emerg Drugs. 9 (1): 9—21. PMID 15155133. doi:10.1517/eoed.9.1.9.32956.
Salomé N, Stemmelin J, Cohen C, Griebel G (2006). „Selective blockade of NK2 or NK3 receptors produces anxiolytic- and antidepressant-like effects in gerbils”. Pharmacol. Biochem. Behav. 83 (4): 533—9. PMID 16624395. doi:10.1016/j.pbb.2006.03.013.
Louis C, Stemmelin J, Boulay D, Bergis O, Cohen C, Griebel G (2008). „Additional evidence for anxiolytic- and antidepressant-like activities of saredutant (SR48968), an antagonist at the neurokinin-2 receptor in various rodent-models”. Pharmacol. Biochem. Behav. 89 (1): 36—45. PMID 18045668. doi:10.1016/j.pbb.2007.10.020.
Spooren W, Riemer C, Meltzer H (2005). „Opinion: NK3 receptor antagonists: the next generation of antipsychotics?”. Nat Rev Drug Discov. 4 (12): 967—75. PMID 16341062. doi:10.1038/nrd1905.
Chahl LA (2006). „Tachykinins and neuropsychiatric disorders”. Curr Drug Targets. 7 (8): 993—1003. PMID 16918327. doi:10.2174/138945006778019309. Архивирано из оригинала 28. 03. 2009. г. Приступљено 09. 10. 2018.
Groneberg DA, Harrison S, Dinh QT, Geppetti P, Fischer A (2006). „Tachykinins in the respiratory tract”. Curr Drug Targets. 7 (8): 1005—10. PMID 16918328. doi:10.2174/138945006778019318. Архивирано из оригинала 28. 03. 2009. г. Приступљено 09. 10. 2018.
Improta G, Broccardo M (2006). „Tachykinins: role in human gastrointestinal tract physiology and pathology”. Curr Drug Targets. 7 (8): 1021—9. PMID 16918330. doi:10.2174/138945006778019354. Архивирано из оригинала 28. 03. 2009. г. Приступљено 09. 10. 2018.
Boot JD; de Haas S; Tarasevych S; et al. (2007). „Effect of an NK1/NK2 receptor antagonist on airway responses and inflammation to allergen in asthma”. Am. J. Respir. Crit. Care Med. 175 (5): 450—7. PMID 17170385. doi:10.1164/rccm.200608-1186OC.
Navari RM (2007). „Fosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting”. Expert Opin Investig Drugs. 16 (12): 1977—85. PMID 18042005. doi:10.1517/13543784.16.12.1977.
Hickman MA; Cox SR; Mahabir S; et al. (2008). „Safety, pharmacokinetics and use of the novel NK-1 receptor antagonist maropitant (Cerenia) for the prevention of emesis and motion sickness in cats”. J. Vet. Pharmacol. Ther. 31 (3): 220—9. PMID 18471143. doi:10.1111/j.1365-2885.2008.00952.x.
Quartara L, Altamura M (2006). „Tachykinin receptors antagonists: from research to clinic”. Curr Drug Targets. 7 (8): 975—92. PMID 16918326. doi:10.2174/138945006778019381. Архивирано из оригинала 28. 03. 2009. г. Приступљено 09. 10. 2018.

web.archive.org

Chahl LA (2006). „Tachykinins and neuropsychiatric disorders”. Curr Drug Targets. 7 (8): 993—1003. PMID 16918327. doi:10.2174/138945006778019309. Архивирано из оригинала 28. 03. 2009. г. Приступљено 09. 10. 2018.
Groneberg DA, Harrison S, Dinh QT, Geppetti P, Fischer A (2006). „Tachykinins in the respiratory tract”. Curr Drug Targets. 7 (8): 1005—10. PMID 16918328. doi:10.2174/138945006778019318. Архивирано из оригинала 28. 03. 2009. г. Приступљено 09. 10. 2018.
Improta G, Broccardo M (2006). „Tachykinins: role in human gastrointestinal tract physiology and pathology”. Curr Drug Targets. 7 (8): 1021—9. PMID 16918330. doi:10.2174/138945006778019354. Архивирано из оригинала 28. 03. 2009. г. Приступљено 09. 10. 2018.
Quartara L, Altamura M (2006). „Tachykinin receptors antagonists: from research to clinic”. Curr Drug Targets. 7 (8): 975—92. PMID 16918326. doi:10.2174/138945006778019381. Архивирано из оригинала 28. 03. 2009. г. Приступљено 09. 10. 2018.